2-Isopropylmalic acid

CAS No. 3237-44-3

2-Isopropylmalic acid( —— )

Catalog No. M37800 CAS No. 3237-44-3

2-Isopropylmalic acid is a natural product.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 65 Get Quote
5MG 89 Get Quote
10MG 129 Get Quote
25MG 207 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    2-Isopropylmalic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    2-Isopropylmalic acid is a natural product.
  • Description
    α-Isopropylmalate (α-IPM) is the leucine biosynthetic precursor in Yeast.
  • In Vitro
    α-Isopropylmalate (500 μM) increases LEU3 protein (Leu3p)-dependent transcription.α-Isopropylmalate (10 mM, 48 h) increases reporter gene expression in preadipocytes (30A5).
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    3237-44-3
  • Formula Weight
    176.17
  • Molecular Formula
    C7H12O5
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : ≥ 250 mg/mL (1419.08 mM)
  • SMILES
    CC(C)C(O)(CC(O)=O)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sze JY, et al. In vitro transcriptional activation by a metabolic intermediate: activation by Leu3 depends on alpha-isopropylmalate. Science. 1992 Nov 13;258(5085):1143-5. ?
molnova catalog
related products
  • 2"-O-β-L-Galorientin

    2"-O-β-L-Galorientin is a natual product isaolated from?Trollius chinensis Bunge.

  • Kinetensin

    Kinetensin is a neurotensin-like peptide.

  • Atracurium besylate

    Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.